Fig. 1: PPP2R1A mutations are associated with longer survival after ICB in OCCC.
From: PPP2R1A mutations portend improved survival after cancer immunotherapy
a, Schematic of the clinical trial design, sampling and subsequent analyses. Part of the figure was created using BioRender. b, The overall responses and outcomes of the enrolled patients. The starting points represent the time of the baseline clinical evaluation, and the end points represent the time of patient death or data cut-off. Response assessments shown are from only during the trial. CR, complete response (defined according to RECIST v.1.1, modified for immunotherapy); mut, mutated; PD, progressive disease; PR, partial response; SD, stable disease; WT, wild-type. c, Kaplan–Meier survival analysis of OS based on the PPP2R1A mutation status. d, Kaplan–Meier survival analysis of OS based on the ARID1A mutation status in the subgroup of patients with wild-type PPP2R1A. e, Kaplan–Meier survival analysis of OS based on the PPP2R1A mutation status in the subgroup of patients with ARID1A mutations. f, Representative patient computed tomography (CT) scan images (patient (Pt) 0) demonstrating the disease burden over time, with initial progression then response. CT scan images are shown at the baseline, and at 12, 24 and 36 weeks of therapy; the arrowheads mark representative tumour lesions. g, The changes in target lesion responses, as revealed by the sum of tumour diameters. The end points represent the time of last clinical evaluations while the patients were on trial. For patient 31 (asterisk), follow-up was continued until 70.4 months from the baseline. h, The best overall target lesion response when the patients were on trial, as revealed by the percentage changes from the baseline of tumour burdens. Data above 100 were truncated. For c–e, P values were calculated using one-sided log-rank tests.
